Literature DB >> 10598935

Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats.

W Meng1, X Wang, M Asahi, T Kano, K Asahi, R H Ackerman, E H Lo.   

Abstract

Tissue type plasminogen activator (tPA) can be effective therapy for embolic stroke by restoring cerebral perfusion. However, a recent experimental study showed that tPA increased infarct size in a mouse model of transient focal ischemia, suggesting a possible adverse effect of tPA on ischemic tissue per se. In this report, the effects of tPA in two rat models of cerebral ischemia were compared. In experiment 1, rats were subjected to focal ischemia via injection of autologous clots into the middle cerebral artery territory. Two hours after clot injection, rats were treated with 10 mg/kg tPA or normal saline. Perfusion-sensitive computed tomography scanning showed that tPA restored cerebral perfusion in this thromboembolic model. Treatment with tPA significantly reduced ischemic lesion volumes measured at 24 hours by >60%. In experiment 2, three groups of rats were subjected to focal ischemia via a mechanical approach in which a silicon-coated filament was used intraluminally to occlude the origin of the middle cerebral artery. In two groups, the filament was withdrawn after 2 hours to allow for reperfusion, and then rats were randomly treated with 10 mg/kg tPA or normal saline. In the third group, rats were not treated and the filament was not withdrawn so that permanent focal ischemia was present. In this experiment, tPA did not significantly alter lesion volumes after 2 hours of transient focal ischemia. In contrast, permanent ischemia significantly increased lesion volumes by 55% compared with transient ischemia. These results indicate that in these rat models of focal cerebral ischemia, tPA did not have detectable negative effects. Other potentially negative effects of tPA may be dependent on choice of animal species and model systems.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10598935     DOI: 10.1097/00004647-199912000-00004

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  18 in total

Review 1.  The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity.

Authors:  George W J Harston; Brad A Sutherland; James Kennedy; Alastair M Buchan
Journal:  J Cereb Blood Flow Metab       Date:  2010-08-25       Impact factor: 6.200

2.  Comparative Analysis of Different Methods of Ischemia/Reperfusion in Hyperglycemic Stroke Outcomes: Interaction with tPA.

Authors:  Sherif Hafez; Md Nasrul Hoda; Xinyue Guo; Maribeth H Johnson; Susan C Fagan; Adviye Ergul
Journal:  Transl Stroke Res       Date:  2015-02-17       Impact factor: 6.829

Review 3.  Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders.

Authors:  William M Armstead; Kumkum Ganguly; J W Kiessling; John Riley; Xiao-Han Chen; Douglas H Smith; Sherman C Stein; Abd A R Higazi; Douglas B Cines; Khalil Bdeir; Sergei Zaitsev; Vladimir R Muzykantov
Journal:  J Neurochem       Date:  2010-04       Impact factor: 5.372

Review 4.  Can the time window for administration of thrombolytics in stroke be increased?

Authors:  Geoffrey A Donnan; David W Howells; Romesh Markus; Danilo Toni; Stephen M Davis
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

5.  Thioredoxin-interacting protein: a novel target for neuroprotection in experimental thromboembolic stroke in mice.

Authors:  Tauheed Ishrat; Islam N Mohamed; Bindu Pillai; Sahar Soliman; Abdelrahman Y Fouda; Adviye Ergul; Azza B El-Remessy; Susan C Fagan
Journal:  Mol Neurobiol       Date:  2014-06-18       Impact factor: 5.590

Review 6.  Stroke, Vascular Dementia, and Alzheimer's Disease: Molecular Links.

Authors:  Murali Vijayan; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2016-09-06       Impact factor: 4.472

Review 7.  Tissue-type plasminogen activator as a therapeutic target in stroke.

Authors:  Iordanis Gravanis; Stella E Tsirka
Journal:  Expert Opin Ther Targets       Date:  2008-02       Impact factor: 6.902

8.  Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke.

Authors:  Tauheed Ishrat; Bindu Pillai; Adviye Ergul; Sherif Hafez; Susan C Fagan
Journal:  Neurochem Res       Date:  2013-11-06       Impact factor: 3.996

9.  Remote ischemic perconditioning is effective alone and in combination with intravenous tissue-type plasminogen activator in murine model of embolic stroke.

Authors:  Md Nasrul Hoda; Shahneela Siddiqui; Samuel Herberg; Sudharsan Periyasamy-Thandavan; Kanchan Bhatia; Sherif S Hafez; Maribeth H Johnson; William D Hill; Adviye Ergul; Susan C Fagan; David C Hess
Journal:  Stroke       Date:  2012-08-21       Impact factor: 7.914

10.  A secretory phospholipase A2-mediated neuroprotection and anti-apoptosis.

Authors:  Arunmozhiarasi Armugam; Charmian D N Cher; KaiYing Lim; Dawn C I Koh; David W Howells; Kandiah Jeyaseelan
Journal:  BMC Neurosci       Date:  2009-09-23       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.